Inhibrx Biosciences Files Form 8-K with Corporate Presentation and Clinical Data

Inhibrx Biosciences, Inc. filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission on September 28, 2026. The filing includes an updated corporate presentation accessible via the company's website, which details the company's business strategy and clinical development progress.

The presentation outlines the company's mission to develop biologic treatments for life-threatening conditions and highlights its internal capabilities in protein engineering, cell biology, and clinical development. As of August 6, 2026, the company reported having approximately 110 employees and common stock outstanding of 14.7 million shares.

Financial highlights from the presentation show the company held $219.5 million in cash and cash equivalents as of August 6, 2026. The company noted that this figure includes 4.0 million employee and Board of Directors option reserves, approximately 1 million pre-funded warrants, and 0.2 million warrants outstanding.

The presentation focuses on the company's lead product candidate, INBRX-106, a hexavalent OX40 agonist. Data presented for INBRX-106 in combination with pembrolizumab (pembro) showed an Objective Response Rate (ORR) of 80% compared to 33% for pembrolizumab alone in a randomized, first-line Head and Neck Squamous Cell Carcinoma (HNSCC) study. The combination also demonstrated a higher Complete Response Rate (30% vs. 0%) and a higher Progression-Free Survival rate (Not Reached vs. 4.6 months).

The company detailed the design of the HexAgon study, a seamless Phase 2/3 trial in first-line recurrent/metastatic HNSCC. The study is randomized 1:1 to compare INBRX-106 plus pembrolizumab versus pembrolizumab alone. The primary endpoints of the Phase 3 portion are Progression-Free Survival (PFS) and Overall Survival (OS). Secondary endpoints include ORR, Duration of Response (DOR), Clinical Benefit Rate (CBR), and safety.

Regarding its second lead candidate, ozekibart (INBRX-109), the company stated it plans to meet with the U.S. Food and Drug Administration to discuss the design of a registrational trial for first-line colorectal cancer and a potential accelerated regulatory pathway for fourth-line colorectal cancer. The company also noted potential milestones for ozekibart, including potential approval and first commercial launch for metastatic or unresectable chondrosarcoma in the second half of 2027.